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Probabilistic sensitivity analyses were also performed using
Monte Carlo simulations.
Results: Based on our Markov model, AZT-3TC-efavirenz
had the lowest cost of treatment (USD $12.09 per day)
and the highest rate of success (69%). It was the primary
cost-effective HAART for HIV/AIDS in Colombia. AZT-3TC-
efavirenz dominated all other HAART treatments. Results
were generally robust within ranges tested.
Conclusion: In Colombia, antiretroviral therapy will lead
to major survival beneﬁts and is cost-effective by World
Health Organization criteria. The availability of second-line
regimens will further increase survival, but their cost-
effectiveness depends on their relative cost compared with
ﬁrst-line regimens.
doi:10.1016/j.ijid.2010.02.2027
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Prevalence of metabolic abnormalities and metabolic syn-
drome in a cohort of hispanic patients on HAART
E. Bissio1,∗, G. Lopardo2
1 FUNCEI, Buenos Aires, Argentina
2 Corunna, Argentina
Background: Metabolic abnormalities are a well known
side-effect of HAART. However, some studies show similar
prevalences of metabolic syndrome in patients on HAART
and the general population. According to different studies,
prevalence of metabolic syndrome in the general popula-
tion ranges from 23.7% to 24.6% using the ATP III deﬁnition.
The aim of this study was to determine the prevalence
of metabolic abnormalities and metabolic syndrome in a
cohort of hispanic patients on HAART attending an ID Clinic
in Buenos Aires, Argentina.
Methods: Retrospective cross-sectional study. The
records from the patients were reviewed to determine
prevalence of the metabolic syndrome (as deﬁned by the
NCEP ATP III Update), and the prevalence of metabolic
abnormalities.
Results: The cohort was composed of 78 hispanic
patients on stable HAART for at least 6 months (mean age:
40.89± 8.55 years [range: 22—64]; 9% were women). Mean
CD4: 583± 282 cells/mm3; median VL: 50 (IQR: 50—50).
The general prevalence of the metabolic syndrome was
24.7% (95% CI 15.6-36.8). The prevalence among patients on
a protease inhibitor(PI)-based regimen (n = 15) was 26.7%,
versus 24.2% among those without PI (p =NS). In this last
group, those on efavirenz (n = 43) had a prevalence of 26.2%
compared to 14.3% those on nevirapine (p < 0.05). The age-
speciﬁc prevalence in the 30-39 years group was 22.2%, and
32.1% in the 40-49 years group. The prevalence of hyper-
trigliceridemia was 47.4%, but differed according to therapy
group (PI, EFV or NVP; mean values (mg/dL): 240± 322.76;
165± 109 and 150± 80.4; respectively), and increased with
age group (20-29: 33%, 30-39: 45.7%, 40-49: 50%). General
prevalence of low HDLwas 37.3% (women: 42%, men: 38.2%);
there was no difference between patients with or without
PI; but in this last group, prevalence among those on EFV was
42.5% vs 21.41% in those on nevirapine (p < 0.05). Hyperten-
sion prevalence was 39.5%.
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Conclusion: In this cohort, prevalence of the metabolic
yndrome was similar to the prevalence in the gen-
ral population. However, patients on protease inhibitors
nd efavirenz had a higher prevalence than those on
evirapine (and the general population). Drug-induced
ypertrigliceridemia seems to be one of the major drivers
eading to the emergence of the metabolic syndrome among
hese patients.
oi:10.1016/j.ijid.2010.02.2028
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edication errors in patients receiving antiretroviral
herapy at an urban hospital
. Zangeneh1,∗, G. Dickinson2
University of Miami, 33125, FL, USA
Miami VA Medical Center, Miami, ﬂ, USA
Background: Combination Antiretroviral therapy (ART)
as decreased morbidity and mortality for persons with
uman immunodeﬁciency virus (HIV) infection. These
omplex regimens involve three or more agents, and
here are many potential errors. The errors in prescrib-
ng ART may lead to adverse/toxic effects, treatment
ailure, and drug resistance. We evaluated medication
rrors occurring among patients receiving ART at the
iami VAMC to identify potential interventions to decrease
rrors.
Methods: This was a retrospective study utilizing a med-
cal chart review to evaluate medication prescribing errors
ccurring among patients who had received ART during Jan-
ary 1 through December 31, 2007 at the Miami VAMC.
sing the DHHS guidelines for HIV therapy as a source, we
creened for the following prescribing errors: inappropri-
te dosing, use of inappropriate regimens/combinations,
se of other medications and ART when contraindicated,
ailure to adjust for renal insufﬁciency, and insufﬁcient mon-
toring. In addition, we evaluated the frequency of errors
ccurring during admission in comparison to the out patient
linic.
Results: The medical charts of 833 patients of whom
14 (62%) were receiving ART were reviewed. A total of 24
igniﬁcant prescribing errors involving antiretrovirals were
etected. Themost common errors involved failure to adjust
or renal insufﬁciency (54%) followed by use of contraindi-
ated combinations with potential for drug interactions
46%). Overall, 17% of the errors occurred while the patient
as admitted to the hospital. Although 75% (3) of the errors
n the inpatient group were due to renal dosing as opposed to
5.5% (10) in the outpatient group; this was not statistically
igniﬁcant. Similarly, there was no statistical difference
egarding contraindicated combination medications among
oth groups.
Conclusion: In this Patient population, the most fre-
uent errors involved failure to adjust ART in the face
f renal insufﬁciency and the co-administration of con-
raindicated medications with ART. These errors can be
voided by automated alerts in the computerized medical
ecord used at this facility and emphasizing to physicians
he importance of adjusting dosage or changing the ART
o account for renal insufﬁciency. System-based interven-
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ions can be developed to prevent these errors before they
ccur.
oi:10.1016/j.ijid.2010.02.2029
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omparison of the effectiveness of low dose Indi-
avir/ritonavir (IDV/r) versus Atazanavir/ritonavir (ATV/r)
ased antiretroviral therapy in NNRTI experienced HIV-1
nfected patients in India
. Patel1,∗, A.K. Patel1, J.K. Patel1, E. Naik2, J. Duan2, R.
anjan1, S. Hamisu2
Vedanta Institute of Medical Sciences, 380009, Gujarat,
ndia
University of South Florida, Tampa, FL, USA
Background: Currently, data on the effectiveness of sec-
nd line antiretroviral regimens using IDV/r and ATV/r along
ith two back bone nucleosides in resource poor settings
s limited. It is important to compare the potency and efﬁ-
acy of each regimen in order to establish utility on clinical
utcomes. We sought to evaluate viro-immunologic deter-
inants of response to IDV400/r BID and ATV300/r QD in
re-treated HIV-infected patients.
Methods: Prospective cohort study on 441 patients who
xperienced immunological or clinical failure to ﬁrst line
NRTI-based treatment and were enrolled in a 96-week
tudy follow-up. Based on the patients ability to pay, 321
72.8%) and 120 (27.2%) patients were prescribed reg-
mens containing low dose of IDV/r 400/100mg BID or
TV/r 300/100mg QD with 2NRTI, respectively. Successful
mmunologic response to treatment was deﬁned by annual
ise in absolute CD4 count of 100/cmm or more from base-
ine, while successful virologic response was deﬁned by
VL < 400 copies/ml at 12 or 24 weeks after initiation of
reatment. Multivariate Cox Proportional Hazards Model was
sed to assess comparative effectiveness of treatment regi-
ens with correction for intra-cluster correlation by means
f the Robust Sandwich Estimator.
Results: Both the groups had similar age, sex and weight
istribution. (p = 0.302, 0.232 & 0.459 respectively). A total
f 63 patients (14.8%) had failed second line treatments, 53
atients (17.2%) were using IDV/r while 10 patients (8.5%)
ere on ATV/r. Patients who took IDV/r were more than
wice as likely to experience treatment failure as com-
ared to those on ATV/r (HR 2.18; 95% CI 1.14, 4.15). A
igniﬁcant treatment-response interaction was observed for
atient weight and prior combination of NRTI use. Success-
ul response was not different between the two groups when
atients weighed < 55 kg at baseline (log rank p value = 1.00)
n contrast to the ﬁndings among individuals weighing ‘‘55 kg
p = <0.0001). Patients with one NRTI recycled, ATV/r was
ound to be superior to IDV/r (p = 0.01) while among those
ith both NRTI recycled, there was no difference in response
o either group (p = 0.61).
Conclusion: We found that Successful response to second
ine therapy was twice as likely in the ATV/r group; however,
his difference was eliminated in patients less than 55 kg.
oi:10.1016/j.ijid.2010.02.2030
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RTI resistance proﬁle of the subtype F HIV-1 strains from
hildren and adolescents treated with multiple antiretro-
iral drugs
. Jugulete1,∗, M.L. Luminos2, M. Mardarescu3, D. Otelea4,
. Merisescu5
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, sector 2, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Disease ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases, Bucharest, Romania
Background: The HIV epidemic in Romania is character-
zed by the existence of a large cohort of children and
dolescents that have been infected in the late eighties.
ost of these patients have been under treatment for the
ast ten years: all of them are currently on HAART but
heir majority has experienced a period (years) of either
onotherapy (AZT) or bitherapy (AZT with 3TC or ddC). This
tudy examines resistance proﬁles in the RT gene of HIV-1
trains obtained from these patients.
Methods: We have studied resistance tests on antiretro-
iral therapy of experienced children’s and adolescents with
IV infection and AIDS hospitalized in National Institute
f Infectious Diseases ‘‘Prof. dr. Matei Bal#’’. On these
atients we have evaluated: antiretroviral therapy, number
f antiretroviral schemes, the type of resistance muta-
ions selected on Nucleoside Reverstranscriptase Inhibitors
NRTI’s) and the implications on to established of antiretro-
iral therapy, also.
Results: The most frequent mutations were: M184V/I -
8.8%, T215F/Y — 74.4%, D67N — 68.2%, K219E/Q — 66.6%,
70R — 56.9%, M41L — 41.4%. The thymidine analogue
utations (TAMs) were common and frequently associated
ith M184V. Within the TAM group, T215F/Y was frequently
ssociated with D67N, K70R and/or K219E/Q. V75T/V was
ssociated with K219E but only seldom with K219Q. The mul-
iresistention on experimented HIV infected children was
.2% (Q151M, 69ins, K65R).
Conclusion: The mutation associations in the RT gene
f the subtype F HIV-1 strains are partly different from
hose communicated for the subtype B strains and therefore
equire further scrutiny.
oi:10.1016/j.ijid.2010.02.2031
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mplementation of HLA-B*5701 genetic screening prior to
bacavir prescription in Georgia
. Dvali ∗, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M.
archava, L. Gatserelia, T. TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research
enter, Tbilisi, Georgia
Background: A hypersensitivity reaction to abacavir
evelops in approximately 2-8% of patients receiving this
